What is the global market size of In Situ Hybridization ISH Market?

In Situ Hybridization ISH Market size was valued at USD 1.34 billion in 2022 and is poised to grow from USD 1.44 billion in 2023 to USD 2.42 billion by 2031, growing at a CAGR of 6.9% in the forecast period (2024-2031).

In Situ Hybridization ISH Market Size

In Situ Hybridization ISH Market Insights

Global In Situ Hybridization ISH Market size was valued at USD 2.1 billion in 2023 and is poised to grow from USD 2.36 billion in 2024 to USD 6.06 billion by 2032, growing at a CAGR of 12.5% during the forecast period (2025-2032).

Nucleic acids can be found and localized in cells, histological sections, and other biological samples using the molecular biology technique known as in-situ hybridization (ISH). It has many uses in molecular diagnosis, gene editing, and recombinant DNA technology because it enables scientists to observe how nucleic acids are distributed throughout the genome of the target organism. Due to ISH's high sensitivity, accurate localization, and effective quantification of sample nucleic acids, as well as its use in more and more fields including molecular biology, immunology, developmental biology, hematopathology, and phylogenetic analysis, the market is growing in terms of revenue.

Researchers have been able to learn more about disease prognosis, drug discovery and development, and the use of biomarkers through the detection of mRNA molecules and the study of the functional state of cells, among other major applications. Several research institutions and organizations have engaged in extensive R&D over the past few years to create a technology that can analyze the molecular profiles of individual cells. For instance, Proximity Ligation in situ Hybridization, an in situ hybridization method developed by Bio-protocol. The method is praised for its high performance, affordability, rapid multiplexing, and ease of use.

US In Situ Hybridization ISH Market is poised to grow at a sustainable CAGR for the next forecast year.

FAQs

Global in situ hybridization (ISH) market is highly competitive and somewhat fragmented. To maintain a competitive edge, the major industry participants are continually implementing various growth strategies. Innovations, mergers, and acquisitions, collaborations and partnerships are adopted by these players to thrive in the competitive market. In order to provide industries with the most effective and economical solutions, the major market players are also continually concentrating on R&D. 'Abbott (US) ', 'F. Hoffmann-La Roche AG (Switzerland) ', 'Thermo Fisher Scientific Inc. (US) ', 'Danaher (US) ', 'Agilent Technologies, Inc. (US) ', 'Biocare Medical, LLC (US) ', 'Bio-Techne Corporation (US) ', 'QIAGEN N.V. (Netherlands) ', 'Merck KGaA (Germany) ', 'PerkinElmer (US) ', 'Enzo Biochem (US) ', 'Bio-Rad Laboratories (US) ', 'Abnova Corporation (Taiwan) ', 'BioGenex Laboratories (US) ', 'OpGen (US) ', 'Bio SB (US) ', 'Abcam (UK) ', 'Zytomed Systems GmbH (Germany) ', 'NeoGenomics Laboratories (US) ', 'BioView (Israel)'

Over the past few years, there has been an increase in cancer cases worldwide. Recurrent genomic abnormalities have been identified as potential initiating factors for a number of cancers as a result of extensive research on human diseases over the past few decades. The integration of cytogenetic assays, such as ISH, with DNA FISH and IHC completes the set of in situ tools available to researchers for the creation, discovery, and application of next-generation diagnostic techniques. A special insight into the interaction between cancer cells and the tumour microenvironment while the cancer is progressing is provided by direct imaging of gene expression in situ at the RNA level. According to GLOBOCAN, there were 43.8 million cancer patients worldwide in 2018 and 9.6 million cancer-related deaths. In 2018, there were roughly 18.1 million new cases reported. By 2040, the number of cases of cancer could rise to 29.5 million, with a mortality rate of 16.5 million. Furthermore, compared to earlier estimates of 400,000, the incidence of haemophilia has tripled to reach 1,125,000, according to research from McMaster University (Canada). France, Canada, Italy, Australia, the UK, and New Zealand are the nation’s most severely impacted. The market will probably benefit from this increase.

With the goal of increasing the sensitivity of in situ hybridization methods, the market is observing developments at a highly encouraging rate. In situ hybridization techniques' range of applications have recently expanded thanks to innovations like strand displacement amplification and molecular beacons. Due to their ability to identify targets with low copy numbers of nucleic acids in samples, some of these cutting-edge techniques have significantly expanded the utility of in situ hybridization in the fields of research and diagnostic pathology.

North America is expected to control the in situ hybridization (ISH) market share. The presence of a sizable number of market participants and the regional government's encouragement of research projects are both responsible for the region's growth. Throughout the forecast period, the region will continue to dominate due to high healthcare costs and strict FDA and Health Canada regulations. The most patents are in the North American market, while the Asia-Pacific market has a higher marginal increase than other markets. Health Canada-funded research institutions and projects are likely to have a small but positive impact on the market. The market is anticipated to grow the fastest in Asia Pacific during the anticipated period. Over the course of the forecast period, increasing the involvement of local authorities in R&D is anticipated to be the main market driver. In the Asia Pacific region, China and India have the two fastest-growing economies.